Hugo Braun

Partner at North Coast Technology Investors

📍 Ann Arbor, Michigan, United States🔄 Updated September 2026💼 6 investments📅 16 years investing🗓 Last invested Jan 2015
VC🌍 United States
6
Total investments
1
Early stage
0
Mid stage
1
Late stage
16y
Years active

Portfolio

6 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2015
BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.
Board Member
2015
BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.
Board Member
2014
The largest, fastest-growing high school sports marketing and media network. Partnered with over 20% of the nation's high schools, VNN connects local sports communities together.
Board Member
2011
Fabrisonic is a unique 3D metal printing manufacturing company. We use an Ultrasonic Additive Manufacturing (UAM) process to build specialized parts. Fabrisonic can weld dissimilar metals, embed sensors and active elements, and create complex geometry within the component. For more information, please visit our website at www.fabrisonic.com.
Board Member
2010
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.
Board Member
2010
MVCA is a nonprofit trade organization designed to bring together venture capital industry participants in the state of Michigan. The organization’s goal is to grow and sustain a vibrant venture capital community in Michigan. MVCA membership includes private and corporate venture capital funds, angel investors, universities and economic development organizations, and service providers. More than 400 individuals are members of MVCA, representing 100+ organizations across the nation.
Experience · 8 entries
All (8)
Investments (6)
Board (6)
2015
Board Member
2015
BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.
Board Member
2015
BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.
2014
Board Member
2014
The largest, fastest-growing high school sports marketing and media network. Partnered with over 20% of the nation's high schools, VNN connects local sports communities together.
2011
Board Member
2011
Fabrisonic is a unique 3D metal printing manufacturing company. We use an Ultrasonic Additive Manufacturing (UAM) process to build specialized parts. Fabrisonic can weld dissimilar metals, embed sensors and active elements, and create complex geometry within the component. For more information, please visit our website at www.fabrisonic.com.
2010
Board Member
2010
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.
Show all 8 entries ↓
Investment activity
2010–2015 · 6 investments
20102201112014120152
Recent (last 2 years)Earlier